Skip to main content

Select Drug Profiles

Pacritinib Shows Good Efficacy in Myelofibrosis: Will the FDA Release Hold on the Drug?
Phoebe Starr
Read More
Lymphoma
Brentuximab Vedotin Improves Responses Lasting 4 Months in Cutaneous T-Cell Lymphoma
Wayne Kuznar
Read More
Leukemia, Oncology
Chemotherapy-Free Induction with Ibrutinib plus Rituximab Shows Unprecedented Efficacy in MCL
Charles Bankhead
Read More
Lymphoma
Pembrolizumab Produces Durable Responses in Relapsed or Refractory Cutaneous T-Cell Lymphoma
Wayne Kuznar
Read More
Lymphoma
R-CHOP Prevails Over Dose-Adjusted EPOCH-R as Standard of Care for Diffuse Large B-Cell Lymphoma
Phoebe Starr
Read More
FDA Approvals
Novel Hypomethylating Agent Active in Patients with High-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Charles Bankhead
Read More
FDA Approvals
Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in AML or High-Risk MDS
Wayne Kuznar
Read More
Multiple Myeloma, Oncology
Elotuzumab-Based Triplet Regimen Stops Progression of High-Risk Smoldering Multiple Myeloma
Wayne Kuznar
Read More
FDA Approvals
The Hematology Pipeline Features New Immune Therapies, and Targeted Agents
Wayne Kuznar
Read More
Perspectives
Health Plans Must Monitor the Oncology Pipeline to Apply Appropriate Coverage Criteria, Maintain Treatment Value
James T. Kenney, RPh, MBA
Read More
Page 97 of 244
Results 961 - 970 of 2438